PSMC1 Antibody

Western Blot: PSMC1 Antibody [NBP1-80959]

Western Blot: PSMC1 Antibody [NBP1-80959] - Analysis in human cell line EFO-21.

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959]

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959] - Staining of human prostate shows moderate nuclear positivity in glandular cells.

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959]

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959] - Staining of human skeletal muscle shows moderate nuclear postivity in myocytes.

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959]

Immunohistochemistry-Paraffin: PSMC1 Antibody [NBP1-80959] - Staining of human pancreas shows moderate nuclear postivity in islets of Langerhans.

Western Blot: PSMC1 Antibody [NBP1-80959] -

Western Blot: PSMC1 Antibody [NBP1-80959] - Characterization of potent & selective NMT inhibitors.(a) Structure & dual NMT1/NMT2 inhibitory potency of compound 1. (b) Crystal structure of 1 (grey) bound to NMT1 in the presence of Myr-CoA showing key water molecules (red spheres) & polar interactions (dashed lines). Key residues (NMT1 numbering) are shown for NMT1 (blue, PDB 4C2Y) & NMT2 (pink, PDB 4C2X), & for NMT1 with 1 bound (green, PDB 4C2Z). Myr-CoA or the Myr-CoA analogue (NHM) is shown in black/grey. Image generated in PyMOL (0.99rc6, DeLano Scientific LLC, http://pymol.sourceforge.net/). (c) Viability (MTS assay) of HeLa cells exposed to compound 1 at concentrations & time points indicated; error bars, s.d. (n=6). (d) Compound 1 inhibits NMT activity dose-dependently in HeLa cells (BPD=before pull-down; PD=after pull-down on streptavidin-coated beads). In-gel fluorescence after YnMyr tagging was quantified (ImageJ) & the response (% relative intensity; error bars, s.d. (n=2)) plotted using GraFit 7.0 to determine TC50 (see Fig. 2a for TC50 determined for compound 1). Western blots against protein substrates of NMT show dose-dependent reduction in enrichment following inhibition (tubulin: non-substrate loading control). (e) Cells treated with azidohomoalanine (AHA), cycloheximide (CHX) or inhibitor 1 (or DMSO vehicle), were lysed & ligated (CuAAC) to an alkyne-TAMRA reagent67. In-gel fluorescence demonstrates inhibition of protein synthesis by CHX, but not by 1. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25255805), licensed under a CC-BY license. Not internally tested by Novus Biologicals.